SCHEMBL5416684

SCHEMBL5416684

C=CCOc1cc(C(=O)N(C)C)cn2cc(C)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
PDE4B Q07343 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
MAPT P10636 1/20 0.33
EGFR P00533 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
POLB P06746 1/20 0.31
RECQL P46063 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PTGER4 P35408 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566371 0.81 KDM4E (0.36) KDM4EPDE4BSMN1; SMN2CHRNB2CHRNB4
SCHEMBL5425817 0.80 BRD4 (0.51) SMN1; SMN2EGFRNPC1RAB9ALRRK2
SCHEMBL5411738 0.74 ALPL (0.33) KDM4ESMN1; SMN2GAAMEN1ALDH1A1
Alcohol SCHEMBL5419944 0.73 GRM5 (0.33) GAATSHR
SCHEMBL5414028 0.68 KDM4E (0.38) KDM4ESMN1; SMN2GAATSHRALDH1A1
SCHEMBL27083079 0.66 GAA (0.36) KDM4ESMN1; SMN2MAPTGAATSHR
Alcohol SCHEMBL5567725 0.65 KDM4E (0.36) KDM4ESMN1; SMN2GAATSHRALDH1A1
SCHEMBL4574508 0.64 KDM4E (0.39) KDM4EPDE4BSMN1; SMN2MAPTGAA
SCHEMBL31393154 0.64 TRPM8 (0.36) EGFR
SCHEMBL31309505 0.64 GRM5 (0.53) KDM4ESMN1; SMN2MAPTGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191334-A1 Tricyclic imidazopyridines ALTANA PHARMA AG (DE) 2007-08-16 US disclosed
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed
EP-1735318-A2 7H-8,9-DIHYDRO-PYRANO(2,3-C)IMIDAZO(1,2A)PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2006-12-27 EP disclosed
EP-1696921-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS Altana Pharma AG (DE) 2006-09-06 EP disclosed
WO-2005090358-A2 7H-8,9-DIHYDRO-PYRANO (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed
WO-2005058325-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191334-A1 Tricyclic imidazopyridines GIPR, SLC10A2, MLNR KDM4E 3809/4885PDE4B 1678/4885SMN1; SMN2 4041/4885
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR KDM4E 4244/4885PDE4B 2374/4885SMN1; SMN2 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.